[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

3 clusters · 6 sources · 29 days · First seen · Last updated

Antibody-drug conjugate market development

Overview

The antibody-drug conjugate (ADC) sector is experiencing significant investment and technological evolution. Individual companies are expanding their capabilities through strategic funding and rights acquisitions, such as Cohance Lifesciences’ $18 million investment in NJ Bio and Aruka Bio, and Medicus Pharma Ltd.’s $27 million agreement with Pfizer Inc. for the compound CD228V.

The market is projected to grow from $14.23 billion in 2025 to $453.9 billion by 2035, maintaining a compound annual growth rate of 12.30%. Recent developments include the 2025 US FDA approvals of Daiichi Sankyo’s DATROWAY for breast cancer and non-small cell lung cancer treatments.

Technological shifts focus on next-generation platforms prioritizing improved drug delivery, linker stability, and higher drug-to-antibody ratios. This includes advancements in antibody discovery, where platforms like Converge Bio utilize target-aware design and multiparameter optimization to balance binding affinity with developability.

Emerging trends include the development of bispecific ADCs. For example, NEOK Bio is developing dual-target therapies for ROR1/B7-H3 and EGFR/MUC1, with Phase 1 clinical trials expected to begin in mid-2026. Successful development continues to rely on specialized bioconjugation expertise to manage the interdependence of the antibody, the linker, and the cytotoxic payload.

Entities

Cohance Lifesciences · Abzena · Converge Bio · Medicus Pharma Ltd. · Daiichi Sankyo

Timeline

  1. [TECHNOLOGY] 2 sources
    Antibody discovery and ADC development drive oncology innovation

    Advancements in antibody discovery platforms and the growing ADC market are driving precision oncology, with the ADC sector projected to reach $36 billion by 2034.

  2. [HEALTH] 2 sources
    Antibody-drug conjugate market projected to reach $453.9 billion by 2035

    The antibody-drug conjugate (ADC) market is forecast to reach $453.9 billion by 2035, driven by advancements in precision medicine, new FDA approvals, and the development of bispecific ADC technologies.

  3. [BUSINESS] 2 sources
    Pharmaceutical companies expand antibody-drug conjugate portfolios

    Cohance Lifesciences is investing $18 million to expand its cancer treatment portfolio, while Medicus Pharma has acquired worldwide rights to a Pfizer antibody-drug conjugate for $27 million.

Sources

chemindigest.com · dreamnews.jp · hhmglobal.com · manufacturingchemist.com · mychesco.com · the-miyanichi.co.jp

This summary has been updated 1 time: see revision history